POST Online Media Lite Edition


Pfizer standalone revenues in 2016 grew 5% operationally

Staff Writer |
Pfizer reported financial results for fourth quarter and full-year 2016.

Article continues below

Pfizer standalone revenues in 2016 grew 5% operationally, excluding the impact of foreign exchange as well as legacy Hospira and legacy Medivation operations.

Fourth-quarter 2016 revenues totaled $13.6 billion, a decline of $420 million, or 3% compared to the prior-year quarter, reflecting an operational decline of $191 million, or 1%, and the unfavorable impact of foreign exchange of $228 million, or 2%.

Excluding the fourth-quarter 2016 contribution from legacy Medivation operations and foreign exchange, revenues declined by $330 million, or 2%.

Of note, there were four fewer selling days in the U.S. and three fewer selling days in international markets during fourth-quarter 2016 compared to fourth-quarter 2015, resulting in a negative impact on fourth-quarter 2016 revenues of approximately $750 million compared to the prior-year quarter.

What to read next

Pfizer revenues decreased $310 million
Pfizer Q4 revenues totaled $14 billion, up 7%
Pfizer Q3 reported revenues decreased $274 million